Sorry but what your source says, that Teva’s Lovenox has a different name—it’s not called Lupenox—and it has different packaging and nothing else about Teva’s Lovenox is different from Lupenox, that sounds like nonsensical to me. Time will tell.
PS I do believe the analyst met the CFO in public when the Lupenox question was asked.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.